Cost-Effectiveness of An Adherence-Enhancing Intervention for Patients with Gout Based on Real-World Data

Abstract

QALY, probabilistic sensitivity analysis revealed that Vedolizumab had a 97% probability of being cost-effective. CONCLUSIONS: Our model predicted that treatment with Vedolizumab improves QALYs and increases time in remission and response compared with Infliximab. In the context of Thailand, Vedolizumab was cost saving and dominated intervention for biologicnaïve patients with moderately to severely active UC.